---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000035"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:23:53.361999+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics FY2023 net loss $219.7M; cash runway into 2H26

## Summary
- Pro forma cash $118.3M as of Dec 31, 2023, expected to fund operations into 2H26.
- Net loss of $219.7M ($1.66/share) vs net income of $35.4M ($0.24/share) in FY2022.
- R&D expenses $71.8M, G&A $40.6M; G&A rose $16.7M on merger costs.
- Topline Phase 2b data for Descartes-08 in MG expected mid-2024; Phase 2 SLE study to start 1H24.
- Special stockholder meeting March 27, 2024 to vote on preferred conversion and 1:20-1:30 reverse stock split.

## SEC filing metadata
- accession: 0001453687-24-000035
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/0001453687-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/rnac-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000035
- JSON: https://secwatch.observer/filing/0001453687-24-000035.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000035.txt

## Key facts
- Earnings Releases
  Cartesian Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.
  - Period: the full year ended December 31, 2023
  - Result: reported results
  source text: Cartesian Therapeutics, Inc. announced its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/0001453687-24-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.